Information Provided By: 
Fly News Breaks for July 17, 2017
TXMD
Jul 17, 2017 | 14:53 EDT
Stifel analyst Annabel Samimy said a lack of clarity is pressuring TherapeuticsMD shares after the company provided a regulatory update on the status of its New Drug Application for TX-004HR, but he thinks there is a high likelihood that the FDA will allow the company to proceed with a post-marketing safety study. Samimy, who still expects a resubmission within weeks and FDA action within two months, keeps a Buy rating and $20 price target on TherapeuticsMD.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
